Literature DB >> 30961952

The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease.

Rebeccah M Brusca1, Iago Pinal-Fernandez2, Kevin Psoter1, Julie J Paik1, Jemima Albayda1, Christopher Mecoli1, Eleni Tiniakou1, Andrew L Mammen2, Lisa Christopher-Stine1, Sonye Danoff1, Cheilonda Johnson3.   

Abstract

PURPOSE: Myositis-associated interstitial lung disease (MA-ILD) is associated with increased mortality, but no prognostic model exists in this population. The ILD-GAP index was developed to predict mortality risk across all subtypes of chronic ILD. The purpose of this study was to validate the ILD-GAP risk prediction model in patients with MA-ILD. PROCEDURES: We completed a retrospective cross-sectional study of patients enrolled in the Johns Hopkins Myositis Center database between 2006 and 2017. Cumulative mortality rates were estimated using the Kaplan-Meier test. Model calibration was determined by using standardized mortality ratios of observed versus expected deaths. MAIN
FINDINGS: 179 participants with MA-ILD were included. The mean baseline percent predicted forced vital capacity was 65.2 ± 20.6%, forced expiratory volume in the first second 65.4 ± 20.4%, and carbon monoxide diffusing capacity 61.6 ± 20.0%. Thirty-two participants died (17.9%). The ILD-GAP model had poor discriminative performance and calibration.
CONCLUSIONS: The ILD-GAP risk prediction model is a poor predictor of mortality among individuals with MA-ILD. The identification of a better predictive model for MA-ILD is needed to help guide care in this patient population.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Calibration; Cross-sectional studies; Interstitial; Lung diseases; Myositis

Year:  2019        PMID: 30961952      PMCID: PMC6461370          DOI: 10.1016/j.rmed.2019.02.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  14 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

Review 3.  Myositis-related interstitial lung disease and antisynthetase syndrome.

Authors:  Joshua Solomon; Jeffrey J Swigris; Kevin K Brown
Journal:  J Bras Pneumol       Date:  2011 Jan-Feb       Impact factor: 2.624

4.  Predicting survival across chronic interstitial lung disease: the ILD-GAP model.

Authors:  Christopher J Ryerson; Eric Vittinghoff; Brett Ley; Joyce S Lee; Joshua J Mooney; Kirk D Jones; Brett M Elicker; Paul J Wolters; Laura L Koth; Talmadge E King; Harold R Collard
Journal:  Chest       Date:  2014-04       Impact factor: 9.410

Review 5.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  Maryam Fathi; Ingrid E Lundberg
Journal:  Curr Opin Rheumatol       Date:  2005-11       Impact factor: 5.006

6.  Validation of the Japanese disease severity classification and the GAP model in Japanese patients with idiopathic pulmonary fibrosis.

Authors:  Shun Kondoh; Hirofumi Chiba; Hirotaka Nishikiori; Yasuaki Umeda; Koji Kuronuma; Mitsuo Otsuka; Gen Yamada; Hirofumi Ohnishi; Mitsuru Mori; Yasuhiro Kondoh; Hiroyuki Taniguchi; Sakae Homma; Hiroki Takahashi
Journal:  Respir Investig       Date:  2016-03-30

7.  Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis.

Authors:  Eun Sun Kim; Sun Mi Choi; Jinwoo Lee; Young Sik Park; Chang-Hoon Lee; Jae-Joon Yim; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Sang-Min Lee
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

8.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  I Marie; E Hachulla; P Chérin; S Dominique; P-Y Hatron; M-F Hellot; B Devulder; S Herson; H Levesque; H Courtois
Journal:  Arthritis Rheum       Date:  2002-12-15

9.  A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391

10.  Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study.

Authors:  Sang Hoon Lee; Song Yee Kim; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Soo Taek Uh; Choon Sik Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Yong Hyun Kim; Jin Woo Song; Sung Woo Park; Moo Suk Park
Journal:  Respir Res       Date:  2016-10-18
View more
  2 in total

1.  Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.

Authors:  Adelle S Jee; Robert Sheehy; Peter Hopkins; Tamera J Corte; Christopher Grainge; Lauren K Troy; Karen Symons; Lissa M Spencer; Paul N Reynolds; Sally Chapman; Sally de Boer; Taryn Reddy; Anne E Holland; Daniel C Chambers; Ian N Glaspole; Helen E Jo; Jane F Bleasel; Jeremy P Wrobel; Leona Dowman; Matthew J S Parker; Margaret L Wilsher; Nicole S L Goh; Yuben Moodley; Gregory J Keir
Journal:  Respirology       Date:  2020-11-24       Impact factor: 6.424

2.  Prediction of long-term mortality by using machine learning models in Chinese patients with connective tissue disease-associated interstitial lung disease.

Authors:  Di Sun; Yu Wang; Qing Liu; Tingting Wang; Pengfei Li; Tianci Jiang; Lingling Dai; Liuqun Jia; Wenjing Zhao; Zhe Cheng
Journal:  Respir Res       Date:  2022-01-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.